BPS 804

Drug Profile

BPS 804

Alternative Names: BPS-804

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator MorphoSys; Novartis
  • Developer Mereo BioPharma; Novartis
  • Class Monoclonal antibodies; Osteoporosis therapies; Small molecules
  • Mechanism of Action SOST protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteogenesis imperfecta
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteogenesis imperfecta
  • Discontinued Hypophosphatasia; Postmenopausal osteoporosis

Most Recent Events

  • 20 Feb 2017 BPS 804 receives Orphan Drug status for Osteogenesis imperfecta in European Union
  • 20 Feb 2017 BPS 804 is accepted for EMA's Adaptive Pathways Programme for Osteogenesis imperfecta
  • 13 Dec 2016 Mereo BioPharma has patent protection for BPS 804 in United Kingdom and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top